Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

William stated in an interview before Jul 25, 2010,where they filed 65 patents in foreign countries in 2010 alone..

http://www.bizjournals.com/phoenix/stories/2010/07/26/focus3.html

Less than 3 months later...The announcement came out on the collaboration of LC Sentinel. The Provista Diagnostics Test with the use of DR-70.Those 65 patents belong to Provista Diagnostics and Radient by the confidentiality agreement by law and common sense....Some would say Provista Diagnostics Provista Diagnostics is not pursuing the lung cancer test, but our great DD has proved them wrong from our recent Russian find where PDX is pursuing investors in Russia and abroad with that Lung cancer Test...65 patents filed is a huge investment to just ignore you understand...imo Wolf

TUSTIN, CA--(Marketwire - 10/13/10) - Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC - News) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97.
http://finance.yahoo.com/news/Radient-Pharmaceuticals-and-iw-1271623575.html
*****************************************************************
Sound off: Patents

William Gartner

William Gartner

1. How many patent applications has your company filed overall, and how many were this year?

2. What has the application process been like for you, and what do you think of the time frame for a response?

3. What do you think of the latest U.S. Supreme Court ruling affecting the patent process, and how will it affect your competitive edge?
William Gartner
President and CEO, Provista Life Sciences LLC

APPLICATIONS: Counting foreign countries, we have filed 186 patents on five different technologies. That includes all of our foreign patents, and approximately 65 of those have been filed this year in the individual countries.

PROCESS: The application process is simple to us because we do so many and have a great bioscience patent attorney.

RULING: The new ruling will have no impact on us. The ACLU v. the U.S. Patent Office and Myriad Genetics will have a huge positive impact on our business if the Supreme Court rules that genes cannot be patented.